Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. Media Center/
  3. Press releases /
  4. Corporate

Corporate

New Real-World Data Show Adults with Type 2 Diabetes, Including Those Taking Multiple Diabetes Medications, Achieve Blood Glucose Treatment Goals After Using INVOKANA®(canagliflozin)

Findings Also Show Some Patients Discontinue Use of Other Blood-Glucose-Lowering Medications after Initiation of INVOKANA®

Real-World Data Presented at American Geriatrics Society Meeting Show Consistent Safety of XARELTO® in Elderly Patients

Results Add to Findings from Ongoing Five-Year Post-Marketing Safety Program of XARELTO® Use in Clinical Practice

Janssen to Showcase Data from Five Compounds Including Daratumumab and IMBRUVICA at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

·Note: This release corresponds to ASCO abstracts LBA8512, 8587, 8590, TPS8609, TPS8608, LBA7005, 7012, TPS8599, TPS8601, 7024, TPS7095, TPS7096, 5005, 5047, 5053, 5014, 5028, TPS5071, TPS5084, 10503, 6537, TPS5606

Janssen Launches U.S. Hispanic Community Initiative to Help Improve Type 2 Diabetes Care

New research shows marked differences between Hispanic and non-Hispanic type 2 diabetes patients in disease perceptions and management approaches, highlighting need for tailored education among patients and healthcare professionals

Ethicon’s HARMONIC FOCUS®+ Shears Now Proven To Produce Vessel Seal Strength Equivalent To Advanced Bipolar Devices

Ultrasonic device known for meticulous dissection now produces lower tissue temperature and less thermal damage critical when working near nerves

New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia

Results served as basis for regulatory filing with U.S. Food and Drug Administration and designation as Priority Review